



RESEARCH

Open Access

Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase II α in human anaplastic astrocytomas - an immunohistochemical study

Andreas H Habberstad^{1*}, Sasha Gulati^{1,2} and Sverre H Torp^{1,3}

Abstract

Background: Histological malignancy grading of astrocytomas can be challenging despite criteria given by the World Health Organisation (WHO). Grading is fundamental for optimal prognostication and treatment, and additional biomarkers are needed to support the histopathological diagnosis. Estimation of proliferative activity has gained much enthusiasm, and the present study was designed to evaluate and compare novel immunohistochemical proliferative markers in human anaplastic astrocytomas.

Methods: Proliferative activity was determined in twenty-seven cases with antibodies reactive against the Ki-67 antigen, mitosin, survivin, pHH3, and DNA topoisomerase II α , and they were mutually compared as well as related to mitotic activity.

Results: The markers correlated well with each other, but poorly with mitoses, probably because of small and squeezed tumour samples, in which identification of mitoses can be difficult. Positive association to overall survival was observed as well.

Conclusions: Our data show that these markers may assist significantly in the evaluation of proliferative activity in anaplastic astrocytomas and even have prognostic value.

Virtual Slides: The virtual slide(s) for this article can be found here: <http://www.diagnosticpathology.diagnomx.eu/vs/2653263345404531>.

Introduction

Diffuse astrocytomas are the most common primary malignant brain tumours in humans. They are characterized by widespread distribution throughout CNS, diffuse and infiltrative growth pattern, and inherent trend to undergo malignant transformation. In general the prognosis is poor despite progress in tumour imaging and treatment.

Histopathologic diagnosis is essential for optimal prognostication and treatment. According to World Health Organization (WHO), diffuse astrocytomas can be divided into diffuse astrocytoma grade II, anaplastic

astrocytoma grade III, and glioblastoma grade IV [1]. Distinction between different tumour grades can be challenging, and limited tumour material is often provided to the pathologist. The number of mitoses is of paramount importance, but can be hard to identify in haematoxylin and eosin (H&E)-stained sections [2].

Since proliferative activity is a reliable method to assess tumour biology, there has been continuous research to find such biological markers. Commonly used is the monoclonal antibody Ki-67/MIB-1 which has proven prognostic and diagnostic power in astrocytic tumours [3,4]. Nevertheless, the application of this antibody is hampered by lack of standardization of the immunohistochemical procedures, significant interlaboratory variability, and considerable overlap between the different malignancy groups [3,4].

* Correspondence: andrehab@stud.ntnu.no

¹Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, Trondheim, Norway
Full list of author information is available at the end of the article

New antibodies reactive against proliferation-associated antigens have been launched and shown to correlate with tumour grade, mitoses, and Ki-67/MIB-1 [5-12]. The core histone protein H3 constitutes a major part of the chromatin and is phosphorylated during mitosis [13,14]. There are reports on the phosphorylated form of histone H3 (pHH3) at serine 10 and its potential clinical role and prognostic value in astrocytomas [5,6].

Another marker is survivin, a member of the inhibitor-of-apoptosis-family, which promotes survival of tumour cells [7,15]. It is commonly expressed in embryonic and neoplastic tissues and barely expressed in normal cells [16]. There is limited experience with survivin immunostaining and prognosis in anaplastic astrocytomas, and conflicting data exist in glioblastomas [8,17,18]. Even the significance of the subcellular localization of this protein appears uncertain [6,17-19]. Further, survivin may promote radiation resistance in glioblastomas [20,21].

Nuclear DNA topoisomerase II α (TII α) serves as an essential enzyme with important function in DNA topology, repair, and replication, and proliferative signals may upregulate the gene expression [22,23]. TII α immunostaining in high grade astrocytomas has been shown to represent a reliable proliferation marker and to provide valuable prognostic information [8-12,24].

Mitotin, also called p330d/CENP-F, is linked with the centromere/kinetochore complex and is expressed during the active phases of the cell cycle with a maximum in G2 and M [25,26]. Increased expression is associated with malignancy grade and survival of astrocytomas [12], however, there are few studies to support this finding.

It appears that current proliferation markers to varying degree hold prognostic significance in human astrocytic tumours, however, the experience in anaplastic astrocytomas is limited. The goal of the present study was to evaluate and compare these novel proliferation markers and consider their prognostic value in a series of anaplastic astrocytomas.

Materials and methods

This study is an extension of a recently published study [27]. A total number of 27 patients with supratentorial anaplastic astrocytomas operated at the Department of Neurosurgery, St. Olav's University Hospital, Trondheim, Norway, in the time period 1998-2006, were included. The extent of tumour resection was determined by postoperative MRI scans. Surgical resection was defined as gross total resection, partial resection, or biopsy. The clinical data were obtained from electronic medical records and included age, sex, symptoms at presentation, tumour localization, treatment modalities, and postoperative survival. Preoperative Karnofsky performance status (KPS) score was retrospectively determined from a routine neurological examination from patient admittance.

The tumour samples consisted of both formalin-fixed and paraffin-embedded cryosections and unfrozen tissue. All haematoxylin and eosin (H&E) stained sections were reviewed by an experienced neuropathologist (SHT), and tumour grading was based on the latest WHO scheme [1]. The commercial antibodies used are shown in Table 1. Four μ m thick sections with representative tumour tissue were incubated with primary antibodies after quenching of endogenous peroxidase activity with 3% hydrogen peroxide and antigen retrieval by pressure cooking. The immunostaining was carried out on a DAKO Autostainer (Dako, Glostrup, Denmark). Visualization of immunoreactivity was performed with DAKO EnVision system with diaminobenzidine as chromogene. Sections were counterstained with haematoxylin. Positive controls were included in each staining run (human tonsils).

For the microscopical analyses a Nikon Eclipse 80i was used. All immunostained sections were scanned for the most densely labelled areas, and calculations were done with the 40x objective, termed microscopic high power fields (HPF), using an ocular grid (0.058 mm²).

Mitotic activity was defined as the number of mitoses in ten consecutive HPFs, whereas mitotic index was calculated as the percentage of mitoses using the ocular

Table 1 Antibodies and immunohistochemical procedures

| Antibody | Source | Type | Clone | Positive control | Dilution | Incubation temperature | Incubation time |
|-------------------------------|--|------------|---------------|------------------|----------|------------------------|-----------------|
| Ki-67/MIB-1 | Dako, Glostrup, DK | Monoclonal | Ki-67 antigen | Tonsil | 1:100 | Room temperature | 40 min |
| PHH3 | Upstate Biotechnology, Millipore, Billerica, USA | Polyclonal | H3 (Ser10) | Tonsil | 1:2000 | Room temperature | 60 min |
| Survivin | Abcam Products, Cambridge, MA, USA | Monoclonal | EP2880Y | Tonsil | 1:250 | Room temperature | 40 min |
| Mitotin | Novus Biologicals, LTD, Cambridge, UK | Monoclonal | 14C10/1D8 | Tonsil | 1:500 | Room temperature | 40 min |
| DNA topoisomerase II α | Dako, Glostrup, DK | Monoclonal | KiS1 | Tonsil | 1:100 | Room temperature | 40 min |

grid. In several tumour samples mitotic counting was difficult or impossible due to small and squeezed biopsies. Cells with positive pHH3 staining were recorded in the same way as mitoses, including only positively stained nuclei with chromatin changes equivalent to mitotic division.

Antibodies against Ki-67, pHH3, survivin, mitosin, and TII α displayed immunoreactive tumour cell nuclei (Figure 1). Only distinctly stained nuclei were counted. The labelling index (LI) was determined by counting at least 1000 tumour cells in the ocular grid in one HPF. If this number of tumour cells could not be obtained, three HPFs were examined. The proliferative index was defined as the percentage of immunoreactive tumour cells out of the total number of cells. This part of the study was executed blindly from any clinical information, and the data were evaluated by spot tests of the results from two independent scientists (SHH and AHH). Regarding survivin immunostaining, the applied monoclonal antibody was reactive against both cytoplasmic and nuclear located protein and we recorded only the latter.

Statistical analyses were assessed using SPSS version 17.0 (SPSS Inc., Chicago, IL) Correlations between variables were identified employing the Spearman's rank correlation (Spearman's rho), survival data by using Kaplan-Meier curves, log rank-, and COX regression test. Cut points for the different variables were set according to the literature or at the median. The p value, from which statistical significance was assumed, was set to $p < 0.05$.

The study was approved by the Regional Committee for Medical Research Ethics and protocols followed the guidelines by the Helsinki Declaration.

Results

General

Twenty-seven patients (10 women and 17 men; median age, 49 yr; age range, 28-78 yr; median KPS, 70; KPS range, 50-90) with anaplastic astrocytomas were included in the study. Clinical data are presented in Table 2. Four of the patients had previously undergone brain surgery for diffuse astrocytoma (WHO grade II).

Proliferative markers

Immunohistochemical data and estimates for mean values for the proliferative markers are shown in Table 3. Correlation computed by the Spearman's rho, showed significant correlation between most of the proliferative markers (Table 4). Only survivin correlated significant to mitotic activity. The strongest correlations were seen between survivin and the pHH3 index ($r_s = 0.779$, $p < 0.001$), survivin and Ki-67/MIB-1 ($r_s = 0.666$, $p < 0.001$), survivin and mitosin ($r_s = 0.627$, $p = 0.001$), TII α and pHH3 mitoses/10HPF ($r_s = 0.611$, $p = 0.001$), survivin and TII α ($r_s = 0.552$, $p = 0.003$), and between mitosin and Ki-67/MIB-1 ($r_s = 0.558$, $p = 0.005$).

Survival

The median survival was 2.4 years (95% CI, 8-48 months). The one-year survival was 73%. Univariate




Figure 1 Proliferation markers in anaplastic astrocytomas. Mitotic figures (arrows) in H&E-stained sections (A). Nuclear immunoreactivity of Ki-67/MIB-1(B), pHH3 stained mitotic figure (arrow) (C), survivin (D), TII α (E), and mitosin (F).

Table 2 Patient characteristics

| Case no. | Age (years)/Sex | Prior brain tumour | KPS ¹ | Resection grade | Radiotherapy | Postoperative survival (months) |
|----------|-------------------|--------------------|------------------|------------------|-------------------|---------------------------------|
| 1 | 28/F ² | No | 90 | GTR ³ | 1.8 Gy × 30 | 54.6 |
| 2 | 32/F | No | 70 | Partial | 2.0 Gy × 30 | 16.0 |
| 3 | 34/F | No | 80 | Partial | 1.8 Gy × 30 | 29.0 |
| 4 | 34/F | No | 80 | Partial | 1.8 Gy × 30 | 94.4+ ⁴ |
| 5 | 36/M ⁵ | No | 70 | Partial | 3.0 Gy × 13 | 11.1 |
| 6 | 37/M | No | 80 | GTR | No | 53.8+ |
| 7 | 38/M | No | 80 | Partial | 2.0 Gy × 30 | 34.8+ |
| 8 | 39/F | No | 70 | GTR | N.D. ⁶ | N.D. |
| 9 | 42/M | No | 70 | GTR | 1.8 Gy × 30 | 92.3+ |
| 10 | 44/F | No | 80 | GTR | No | 58.9+ |
| 11 | 44/M | Low-grade glioma | 90 | Partial | No | 40.9 |
| 12 | 44/M | Low-grade glioma | 80 | Partial | 1.8 Gy × 30 | 29.0+ |
| 13 | 47/M | Low-grade glioma | 90 | GTR | No | 88.8+ |
| 14 | 49/M | No | 50 | Biopsy | No | 0.1 |
| 15 | 49/M | No | 70 | Partial | 2.0 Gy × 30 | 30.2+ |
| 16 | 50/M | Low-grade glioma | 80 | Partial | 1.8 Gy × 30 | 23.4 |
| 17 | 53/M | No | 70 | Partial | 1.8 Gy × 30 | 24.3 |
| 18 | 56/F | No | 70 | Partial | 2.0 Gy × 30 | 17.6 |
| 19 | 57/F | No | 70 | Partial | 1.8 Gy × 30 | 5.5 |
| 20 | 57/F | No | 80 | Partial | 1.8 Gy × 30 | 62.9+ |
| 21 | 57/M | No | 80 | Partial | 1.8 Gy × 30 | 16.4 |
| 22 | 58/M | No | 80 | Partial | 1.8 Gy × 30 | 28.2 |
| 23 | 64/M | No | 70 | GTR | 1.8 Gy × 30 | 75.0+ |
| 24 | 71/M | No | 50 | Biopsy | 3.0 Gy × 13 | 10.1 |
| 25 | 72/M | No | 60 | Biopsy | 1.8 Gy × 30 | 10.9 |
| 26 | 78/F | No | 50 | Biopsy | 3.0 Gy × 13 | 9.7 |
| 27 | 78/M | No | 50 | Biopsy | No | 1.8 |

¹KPS = Karnofsky Performance Status, ²F = Female, ³GTR = Gross total resection, ⁴(+) denotes that the patient is still alive, ⁵M = Male, ⁶N.D. = No data.

COX analyses with overall survival as the dependent variable, demonstrated significant correlation to KPS ($p < 0.001$), tumour surgery ($p < 0.001$), age ($p = 0.016$), pHH3 index ($p = 0.018$), and Ki-67/MIB-1 ($p = 0.031$). Gross total resection and higher KPS independently correlated with overall survival ($p = 0.026$ and $p = 0.001$ respectively) in a multivariate COX analysis.

Log-rank tests and Kaplan-Meier curves were computed for the cut off values of each proliferation marker. Overall survival (OS) was the dependent variable. Ki-67/MIB-1 ≤ 10 versus >10 (mean OS = 58 vs. 25 months, $p = 0.034$) and TII α ≤ 4 versus >4 (mean OS = 65 vs. 26 months, $p = 0.009$) resulted in significant differences (Figure 2), while pHH3 index ≤ 0.8 versus >0.8 showed a trend ($p = 0.089$). The other proliferative markers did not reach statistical significance.

Discussion

In astrocytomas proliferative activity has been positively correlated to tumour grade and prognosis. Small biopsies and intricate histology make diagnosing difficult, and reliable biological markers are highly needed. In this

immunohistochemical study, we demonstrated positive correlation between the proliferation markers Ki-67/MIB-1, mitotin, survivin, pHH3, and DNA topoisomerase II α . Furthermore, Ki67/MIB-1 and pHH3 indicated poorer survival in univariate analyses.

Mitotic activity is fundamental in the histopathologic grading of human astrocytomas. Identification of mitotic figures is hampered by several factors including squeezed cells in stereotactic biopsies, distortion and similarities to chromatin changes in apoptotic and pycnotic cells [2]. We experienced such elements, particularly in small biopsies and in paraffin sections prior used in frozen sections diagnostics. In contrast to others [5,6,28,29] we did not find positive correlations between mitoses and most of the proliferative markers, probably because of the above mentioned factors. Hence, this observation suggests that antibodies against proliferation-associated antigens are useful to obtain an optimal profile of the proliferative activity, especially in small brain tumour samples.

Ki-67/MIB-1 immunostaining worked well and yielded credible results in our study. The LIs displayed a wide range of values that overlap with indices in both grade

Table 3 Results of the immunohistochemical analyses of the proliferation markers

| Case no. | Mitoses/10HPF | Mitotic index | Ki-67/ MIB-1 | PHH3 mitoses/ 10HPF | PHH3 index | TII α | Survivin | Mitosis |
|----------------|-------------------|---------------|-----------------|------------------------|------------|--------------|----------|---------|
| 1 | N.D. ¹ | N.D. | 6.8 | 1 | 0.5 | 1.8 | 2 | 2.4 |
| 2 | 0 | 0 | 3.5 | 1 | 1.7 | 2.5 | 2.7 | 8.5 |
| 3 | 15 | 0.9 | 6.8 | 19 | 0.9 | 10.8 | 5.3 | 3.4 |
| 4 | 1 | 0.6 | 9.2 | 18 | 0.9 | 7.9 | 7.5 | 8.6 |
| 5 | 0 | 0 | 19.0 | 6 | 2.2 | 0 | 5.8 | 3.6 |
| 6 | 2 | 0.4 | 9.2 | 2 | 0.6 | 2 | 3.4 | 3.1 |
| 7 | 0 | 0 | 1.0 | 0 | 0.0 | 0.8 | 0.3 | 0 |
| 8 | 1 | 0.6 | 7.9 | 1 | 0.8 | 2.7 | 3.3 | 3.5 |
| 9 | 0 | 0 | 5.0 | 1 | 0.2 | 0 | 2.4 | 2.5 |
| 10 | 0 | 0 | 2.1 | 3 | 0.6 | 0 | 1.9 | 1.8 |
| 11 | N.D. | N.D. | 6.4 | 10 | 1.3 | 25 | 3.7 | 1.5 |
| 12 | 0 | 0 | 4.2 | 4 | 1.0 | 4 | 2.7 | 1.9 |
| 13 | N.D. | N.D. | 4.4 | 4 | 0.6 | 1.8 | 1.2 | 1.1 |
| 14 | N.D. | N.D. | 8.5 | 8 | 0.8 | 5 | 2.6 | 3.4 |
| 15 | 6 | 0.5 | 22.2 | 9 | 1.1 | 8.2 | 6 | 3.8 |
| 16 | N.D. | N.D. | 8.6 | 1 | 0.5 | 6.1 | 2.5 | 8 |
| 17 | 1 | 0.7 | N.D. | N.D. | N.D. | 4.5 | 3.8 | 2.9 |
| 18 | N.D. | N.D. | 15.0 | 5 | 1.9 | 6 | 4.4 | 2.7 |
| 19 | 0 | 0 | 20.0 | 2 | 0.4 | 5.4 | 2.3 | 1.4 |
| 20 | N.D. | N.D. | 3.2 | 1 | 0.1 | 1.4 | 1.5 | N.D. |
| 21 | N.D. | N.D. | 16.4 | 30 | 1.1 | 6.9 | 3.5 | 4.5 |
| 22 | 2 | 0.5 | 4.0 | 5 | 0.8 | 3.7 | 3.5 | 1.2 |
| 23 | 1 | 0.8 | 12.9 | 15 | 2.0 | 0 | 6.1 | 2.7 |
| 24 | N.D. | N.D. | 4.9 | 16 | 1.5 | 2 | 2 | 2 |
| 25 | 0 | 0 | 16.5 | 24 | 1.7 | 11 | 8.9 | 5.1 |
| 26 | 0 | 0 | 10.2 | 19 | 0.6 | 6.3 | 2.6 | N.D. |
| 27 | 13 | 0.7 | 21.0 | 37 | 2.7 | 13.5 | 9.6 | 9.5 |
| Median | 0.5 | 0.2 | 8.2 | 5 | 0.8 | 4 | 3.3 | 2.9 |
| Minimum | 0 | 0 | 1 | 0 | 0 | 0 | 0.3 | 0 |
| Maximum | 15 | 0.9 | 22.2 | 37 | 2.7 | 25 | 9.6 | 9.5 |
| Mean | 2.3 | 0.3 | 9.6 | 9.3 | 1.0 | 5.2 | 3.8 | 3.6 |
| Std. deviation | 4.5 | 0.3 | 6.3 | 10.0 | 0.7 | 5.4 | 2.3 | 2.5 |
| Variance | 20.2 | 0.1 | 39.6 | 100.2 | 0.5 | 28.9 | 5.2 | 6.4 |

¹N.D. = No Data

II and grade IV astrocytomas [3], and is regarded as the main reason for Ki-67/MIB-1 not being included in the routine histopathological diagnosis of astrocytic tumours [1]. Thus, this marker should not be used alone, but in combination with established histopathological criteria of malignancy.

Proposals for clinical threshold values have been suggested [3] without a consensus being reached. Using a value of 10% [3,7] a significant impact on survival was found, verifying this as a reasonable threshold.

pHH3 is a novel promising proliferation marker in tumour pathology, however the experience in astrocytomas

is limited. In our hands, this antibody provided reliable immunostaining with distinct nuclear positivity in cells with mitotic morphology. Positive correlations with the other proliferative markers were found except mitoses. This discrepancy may be due to the problem to identify mitotic figures in squeezed and small biopsies. Comparison between the number of mitoses and pHH3 positive nuclei, revealed the latter to be higher, in accordance with being a more sensitive marker for mitoses [5,14,29,30]. A major drawback of the pHH3 immunostaining seems to be positivity in non-mitotic cells [14]. This, together with the subjective determination of mitotic morphology, may lead to

Table 4 Relationships between the proliferation markers (Spearman's rank correlation)

| | | Mitoses/10HPF | | | | | |
|---------------------|---------|-------------------------|--------------|---------------|--------------------|--------------|--------------|
| Mitotic index | r_s | .864¹ | | Mitotic index | | | |
| | p value | 0.000 | | | | | |
| Ki-67/MIB-1 | r_s | .292 | .238 | Ki-67/MIB-1 | | | |
| | p value | 0.255 | 0.358 | | | | |
| PHH3 mitoses /10HPF | r_s | .402 | .404 | .543 | PHH3 mitoses/10HPF | | |
| | p value | 0.110 | 0.108 | 0.015 | | | |
| PHH3 index | r_s | .320 | .361 | .470 | .661 | PHH3 index | |
| | p value | 0.211 | 0.154 | 0.015 | 0.000 | | |
| TII α | r_s | .430 | .303 | .479 | .611 | .352 | TII α |
| | p value | 0.075 | 0.222 | 0.013 | 0.001 | 0.078 | |
| Survivin | r_s | .582 | .588 | .666 | .672 | .779 | .552 |
| | p value | 0.011 | 0.010 | 0.000 | 0.000 | 0.000 | 0.003 |
| Mitosis | r_s | .312 | .261 | .558 | .372 | .475 | .443 |
| | p value | 0.223 | 0.311 | 0.005 | 0.074 | 0.019 | 0.027 |
| | | | | | | | 0.001 |


¹ p value < 0,05 is highlighted

misinterpretation. We demonstrated that higher indices were associated with poorer survival in univariate analyses in accordance with others [5]. For this reason pHH3 stands out as a reliable biomarker, however, larger studies are necessary to further elucidate this observation.

Survivin immunoreactivity was located both in the cytoplasm and in the nucleus, as described by others [6,8,18]. The nuclear positivity was in contrast to the cytoplasmic staining, easily detectable and distinct. As the localization of survivin compartments in the nucleus is correlated to cell division and prognosis [6,17,19], only the nuclear positivity was included. Survivin expression showed significant positive correlation with

all of the proliferation markers, suggesting that nuclear survivin positivity can be a reliable proliferation marker in astrocytic tumours. Our data demonstrated no correlation between survivin expression and survival. The literature is contradictory in this matter [8,17-19], and larger studies are needed to clarify this topic. The effect of survivin on radiotherapy resistance is intriguing. If, however, radiotherapy effects depend on the presence or not of survivin, the implication in anaplastic astrocytomas can be limited, as all of the tumours in our material displayed positively stained cells.

The results from our TII α immunostaining correlated well to the other proliferation markers, in



agreement with previous reports [8,11,24]. The number of positively stained nuclei was easily calculated, and was in general of a lower value than the values of Ki-67/MIB-1, as seen in previous studies [11,24]. This result could be explained by the different protein expression throughout the cell-cycle. TII α positive cells in G0- and G1 phase have been reported [9], and may represent a drawback of this marker. Using the median of 4% as a cut-point, TII α was significantly associated with survival in our material. This is in accordance with others using similar cut-points [9] and suggests that TII α could be of prognostic value in astrocytic tumours.

Mitosis also displayed significant correlations to all of the proliferative markers, which is in accordance with studies on other malignancies [26]. Immunoreactive nuclei were easily identified and can be explained by the mitosis expression in S-, G2-, and M phase, and its rapid degradation [25,26]. Our study could not correlate mitosis expression significantly to survival.

Due to the small number of cases, the survival analyses have been carefully interpreted. However, univariate analyses have gathered sense of which markers that could be further investigated in well-designed studies for prognostic relevance.

The caveats of immunohistochemical analyses include different antibodies, different antigens, background staining, and inhomogeneous staining that can contribute to interlaboratory and interobserver variations. Wrong assumptions can also be made as the knowledge of the novel markers is limited. For instance, protein overexpression in tumour cells can represent genetic aneuploidy, mutated genes or increased transcription factors. Additionally, the functions of a proliferative marker may not exclusively be related to the cell cycle, as was the case for the proliferating cell nuclear antigen (PCNA) [31].

Variations in immunoreactivity may be due to different expression during the cell cycle. The recorded wide range of values represents a major drawback of such markers as one will experience considerable overlap between malignancy groups. Thus, one should consider the possibility to introduce a panel of proliferation markers to identify more aggressive astrocytomas.

Conclusion

In conclusion, immunohistochemical determination of proliferative activity in anaplastic astrocytomas using antibodies against Ki-67 antigen, survivin, mitosis, pHH3 and DNA topoisomerase II α , may assist in the histopathological diagnosis, especially because mitoses can be hard to detect. The prognostic value requires further investigation.

Acknowledgements

The authors want to thank Eli Johannessen, Unn S. Granli, and Borgny Ytterhus for skilful technical assistance.

Author details

¹Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, Trondheim, Norway.

²Department of Neurosurgery, St. Olav's University Hospital, Trondheim, Norway. ³Department of Pathology and Medical Genetics, St. Olav's University Hospital, Trondheim, Norway.

Authors' contributions

AHH participated in the immunohistochemical and the statistical analyses, and drafted the manuscript. SG collected clinical information, performed statistical analyses and participated in the design of the study and to draft the manuscript. SHT conceived of the study and participated in its design, coordination and immunohistochemical analyses and helped to draft the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 13 April 2011 Accepted: 24 May 2011 Published: 24 May 2011

References

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P: **The 2007 WHO classification of tumours of the central nervous system.** *Acta Neuropathol* 2007, **114**:97-109.
2. Prayson RA: **Cell proliferation and tumors of the central nervous system. Part 1: Evaluation of mitotic activity.** *J Neuropathol Exp Neurol* 2002, **61**:501-509.
3. Johannessen A, Torp S: **The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas.** *Pathol Oncol Res* 2006, **12**:143-147.
4. Prayson RA: **The utility of MIB-1/Ki-67 immunostaining in the evaluation of central nervous system neoplasms.** *Adv Anat Pathol* 2005, **12**:144-148.
5. Colman H, Giannini C, Huang L, Gonzalez J, Hess K, Bruner J, Fuller G, Langford L, Pelloski C, Aaron J, et al: **Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas.** *Am J Surg Pathol* 2006, **30**:657-664.
6. Liu X, Chen N, Wang X, He Y, Chen X, Huang Y, Yin W, Zhou Q: **Apoptosis and proliferation markers in diffusely infiltrating astrocytomas: profiling of 17 molecules.** *J Neuropathol Exp Neurol* 2006, **65**:905-913.
7. Uematsu M, Ohsawa I, Aokage T, Nishimaki K, Matsumoto K, Takahashi H, Asoh S, Teramoto A, Ohta S: **Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index.** *J Neurooncol* 2005, **72**:231-238.
8. Preusser M, Gelpi E, Matej R, Marosi C, Dieckmann K, Rossler K, Budka H, Hainfellner JA: **No prognostic impact of survivin expression in glioblastoma.** *Acta Neuropathol* 2005, **109**:534-538.
9. Taniguchi K, Wakabayashi T, Yoshida T, Mizuno M, Yoshikawa K, Kikuchi A, Nakashima N, Yoshida J: **Immunohistochemical staining of DNA topoisomerase II α in human gliomas.** *J Neurosurg* 1999, **91**:477-482.
10. Faria MH, Goncalves BP, do Patrocinio RM, de Moraes-Filho MO, Rabenhorst SH: **Expression of Ki-67, topoisomerase II α and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status.** *Neuropathology* 2006, **26**:519-527.
11. Bredel M, Piribauer M, Marosi C, Birner P, Gatterbauer B, Fischer I, Strobel T, Rossler K, Budka H, Hainfellner JA: **High expression of DNA topoisomerase II α and Ki-67 antigen is associated with prolonged survival in glioblastoma patients.** *Eur J Cancer* 2002, **38**:1343-1347.
12. Korkolopoulou P, Patsouris E, Konstantinidou AE, Christodoulou P, Thomas-Tsagli E, Kouzelis K, Angelidakis D, Rologis D, Davaris P: **Mitosis and DNA topoisomerase II α : two novel proliferation markers in the prognostication of diffuse astrocytoma patient survival.** *Appl Immunohistochem Mol Morphol* 2001, **9**:207-214.
13. Juan G, Traganos F, James WM, Ray JM, Roberge M, Sauve DM, Anderson H, Darzynkiewicz Z: **Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis.** *Cytometry* 1998, **32**:71-77.

14. Hendzel MJ, Wei Y, Mancini MA, Van Hooser A, Ranalli T, Brinkley BR, Bazett-Jones DP, Allis CD: **Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation.** *Chromosoma* 1997, **106**:348-360.
15. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC: **Control of apoptosis and mitotic spindle checkpoint by survivin.** *Nature* 1998, **396**:580-584.
16. Li F: **Survivin study: what is the next wave?** *J Cell Physiol* 2003, **197**:8-29.
17. Shirai K, Suzuki Y, Oka K, Noda SE, Katoh H, Itoh J, Itoh H, Ishiuchi S, Sakurai H, Hasegawa M, Nakano T: **Nuclear survivin expression predicts poorer prognosis in glioblastoma.** *J Neurooncol* 2009, **91**:353-358.
18. Saito T, Arifin MT, Hama S, Kajiwara Y, Sugiyama K, Yamasaki F, Hidaka T, Arita K, Kurisu K: **Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker.** *J Neurooncol* 2007, **82**:193-198.
19. Li F, Yang J, Ramnath N, Javle MM, Tan D: **Nuclear or cytoplasmic expression of survivin: what is the significance?** *Int J Cancer* 2005, **114**:509-512.
20. Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA, Robe P, Nestler U, Song Q, Loeffler J: **Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms.** *Oncogene* 2004, **23**:7494-7506.
21. McLaughlin N, Annabi B, Bouzeghrane M, Temme A, Bahary JP, Moumdjian R, Beliveau R: **The Survivin-mediated radioresistant phenotype of glioblastomas is regulated by RhoA and inhibited by the green tea polyphenol (-)-epigallocatechin-3-gallate.** *Brain Res* 2006, **1071**:1-9.
22. Watt PM, Hickson ID: **Structure and function of type II DNA topoisomerases.** *Biochem J* 1994, **303**(Pt 3):681-695.
23. Larsen AK, Skladanowski A, Bojanowski K: **The roles of DNA topoisomerase II during the cell cycle.** *Prog Cell Cycle Res* 1996, **2**:229-239.
24. Ho DM, Hsu CY, Ting LT, Chiang H: **MIB-1 and DNA topoisomerase II alpha could be helpful for predicting long-term survival of patients with glioblastoma.** *Am J Clin Pathol* 2003, **119**:715-722.
25. Zhu X, Mancini MA, Chang KH, Liu CY, Chen CF, Shan B, Jones D, Yang-Feng TL, Lee WH: **Characterization of a novel 350-kilodalton nuclear phosphoprotein that is specifically involved in mitotic-phase progression.** *Mol Cell Biol* 1995, **15**:5017-5029.
26. Varis A, Salmela AL, Kallio MJ: **Cenp-F (mitosin) is more than a mitotic marker.** *Chromosoma* 2006, **115**:288-295.
27. Gulati S, Ytterhus B, Granli US, Gulati M, Lydersen S, Torp SH: **Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas.** *Diagn Pathol* 2010, **5**:18.
28. Giannini C, Scheithauer BW, Burger PC, Christensen MR, Wollan PC, Sebo TJ, Forsyth PA, Hayostek CJ: **Cellular proliferation in pilocytic and diffuse astrocytomas.** *J Neuropathol Exp Neurol* 1999, **58**:46-53.
29. Ladstein RG, Bachmann IM, Straume O, Akslen LA: **Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.** *BMC Cancer* 2010, **10**:140.
30. Ribalta T, McCutcheon IE, Aldape KD, Bruner JM, Fuller GN: **The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria.** *Am J Surg Pathol* 2004, **28**:1532-1536.
31. McCormick D, Hall PA: **The complexities of proliferating cell nuclear antigen.** *Histopathology* 1992, **21**:591-594.

doi:10.1186/1746-1596-6-43

Cite this article as: Habberstad et al.: Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase II α in human anaplastic astrocytomas - an immunohistochemical study. *Diagnostic Pathology* 2011 **6**:43.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

